Research programme: targeted platinum theranostics - Nemucore Medical Innovations

Drug Profile

Research programme: targeted platinum theranostics - Nemucore Medical Innovations

Alternative Names: NMI-350

Latest Information Update: 25 May 2016

Price : $50

At a glance

  • Originator Nemucore Medical Innovations
  • Class Gadolinium-containing contrast agents; Platinum complexes; Radiopharmaceuticals; Sphingolipids
  • Mechanism of Action Diagnostic imaging enhancers; DNA cross linking agents; DNA synthesis inhibitors; Folate receptor 1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Ovarian cancer

Most Recent Events

  • 23 May 2016 Preclinical trials in Ovarian cancer (Diagnosis) in USA (Parenteral)
  • 23 May 2016 Preclinical trials in Ovarian cancer in USA (Parenteral)
  • 12 May 2016 Early research in Ovarian cancer (Diagnosis) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top